​

LB Pharmaceuticals (LBRX) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

LBRX Stock Forecast


LB Pharmaceuticals (LBRX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $59.78, with a high of $80.00 and a low of $35.00. This represents a 49.30% increase from the last price of $40.04.

$15 $28 $41 $54 $67 $80 High: $80 Avg: $59.78 Low: $35 Last Closed Price: $40.04

LBRX Stock Rating


LB Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

LBRX Price Target Upside V Benchmarks


TypeNameUpside
StockLB Pharmaceuticals49.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts-516
Avg Price Target-$61.60$50.50
Last Closing Price$40.04$40.04$40.04
Upside/Downside-53.85%26.12%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 26281--11
Oct, 2617---8
Sep, 2617---8
Aug, 2617---8
Jul, 2615---6
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 09, 2026Sumant KulkarniCanaccord Genuity$65.00$34.6187.81%62.34%
Oct 05, 2026Guggenheim$80.00$34.62131.08%99.80%
Oct 05, 2026Roth Capital$35.00$35.95-2.64%-12.59%
Oct 02, 2026Needham$68.00$37.2882.40%69.83%
Aug 24, 2026Raghuram SelvarajuH.C. Wainwright$60.00$47.6226.00%49.85%
Aug 13, 2026Stifel Nicolaus$53.00$45.3816.79%32.37%
Aug 12, 2026BMO Capital$54.00$45.3319.13%34.87%
Aug 03, 2026Yasmeen RahimiPiper Sandler$78.00$43.1480.81%94.81%
Jul 20, 2026BMO Capital$46.00$30.9048.87%14.89%
Jul 07, 2026Rudy LiWolfe Research$45.00$33.4134.69%12.39%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 12, 2026H.C. WainwrightBuyBuyhold
Oct 12, 2026Raymond JamesBuyupgrade
Oct 05, 2026GuggenheimBuyinitialise
Oct 05, 2026Roth CapitalBuyNeutraldowngrade
Oct 02, 2026NeedhamBuyinitialise
Aug 24, 2026H.C. WainwrightBuyBuyhold
Aug 12, 2026BMO CapitalOutperformOutperformhold
Aug 03, 2026Piper SandlerOverweightOverweighthold
Jul 24, 2026H.C. WainwrightBuyBuyhold
Jul 20, 2026BMO CapitalOutperforminitialise

Financial Forecast


EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-1.91$-3.97
High Forecast$-1.00$-3.30
Low Forecast$-2.69$-5.27
Surprise %--

Revenue Forecast

Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-20M $-16M $-12M $-8M $-4M $0 Dec 25 Dec 26
Dec 25Dec 26
Reported--
Avg Forecast$-6.76M$-14.05M
High Forecast$-3.54M$-11.68M
Low Forecast$-9.52M$-18.65M
Surprise %--

LBRX Forecast FAQ


Is LB Pharmaceuticals stock a buy?

LB Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that LB Pharmaceuticals is a favorable investment for most analysts.

What is LB Pharmaceuticals's price target?

LB Pharmaceuticals's price target, set by 4 Wall Street analysts, averages $59.78 over the next 12 months. The price target range spans from $35 at the low end to $80 at the high end, suggesting a potential 49.30% change from the previous closing price of $40.04.

How does LB Pharmaceuticals stock forecast compare to its benchmarks?

LB Pharmaceuticals's stock forecast shows a 49.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for LB Pharmaceuticals over the past three months?

  • November 2026: 18.18% Strong Buy, 72.73% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 12.50% Strong Buy, 87.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is LB Pharmaceuticals’s EPS forecast?

LB Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.91, marking a 0% decrease from the reported - in 2024. Estimates for the following years are.

What is LB Pharmaceuticals’s revenue forecast?

LB Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported - in 2024. The forecast for.

What is LB Pharmaceuticals’s net income forecast?

LB Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-6.761M, representing a 0% decrease from the reported - in 2024. Projections indicate .